ArticleHemaSphere2026
Prognostic value of flow cytometry in myelodysplastic neoplasms (MDS): Composition of a FCM-prognostic score (FCM-PS) for overall survival.
Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Re: "Can Flow Cytometry Immunophenotyping Predict Cytogenetic Abnormalities in Acute Myeloid Leukemia?"International journal of laboratory hematology · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flow cytometry (FCM) is a co-criterion in myelodysplastic neoplasms (MDS) diagnostics, currently not used for prognostication. This study aimed to develop an FCM-score predicting overall survival (OS) in MDS to improve early clinical patient prognostication. FCM of bone marrow samples was performed for diagnostic purposes in 509 therapy-naïve MDS patients and 77 healthy donors. The following methodology was used: (1) uni- and multivariate Cox proportional hazards regression and Kaplan-Meier curves for OS to assess FCM-parameters' prognostic value; (2) receiver operating characteristic (ROC) curves to test the prognostic superiority of FCM-parameters versus established FCM-scores and clinical risk-scores; and (3) development of a FCM-prognostic score (FCM-PS) based on six FCM-parameters with independent prognostic impact. The final FCM-PS included aberrancies of progenitor cells (increased CD45 mean fluorescence intensity [MFI]-ratio of lymphocytes and myeloid progenitor cells, decreased % of lymphatic progenitor cells), granulopoiesis (increased CD33 MFI, decreased sideward scatter [SSC]-ratio of granulopoiesis and lymphocytes), lymphocytes (increased % of B-lymphocytes), and plasmacytoid dendritic cells (increased %). FCM-PS outperformed established scores for OS (hazard ratio [HR] 4.08 [95% CI 2.54-6.55] vs. Ogata-score: 2.44 [1.61-3.70], International Prognostic Scoring System-Revised [IPSS-R]: 2.37 [1.61-3.49], International Prognostic Scoring System-Molecular [IPSS-M]: 0.816 [0.303-2.196]). Patients in the FCM-PS low score category showed significantly better OS (P < 0.0001). Further, FCM-PS allowed discrimination within IPSS-R area under the curve [AUC]: 0.70 vs. 0.62) and IPSS-M (AUC: 0.75 vs. 0.48) subgroups. Validation of the prognostic FCM-PS in an independent patient cohort confirmed good discrimination performance (AUC: 0.70). We introduce a unique, easy-to-use prognostic FCM-PS score (panel: CD45/CD34/CD117/CD33/CD19/CD123/HLA-DR) for OS in MDS, allowing refined risk stratification for IPSS-R subgroups.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.